TERBINAFINE-WT terbinafine (as hydrochloride) 250 mg tablet blister pack

Pays: Australie

Langue: anglais

Source: Department of Health (Therapeutic Goods Administration)

Ingrédients actifs:

terbinafine hydrochloride, Quantity: 281.28 mg

Disponible depuis:

Medis Pharma Pty Ltd

DCI (Dénomination commune internationale):

terbinafine hydrochloride

forme pharmaceutique:

Tablet, uncoated

Composition:

Excipient Ingredients: microcrystalline cellulose; colloidal anhydrous silica; sodium starch glycollate type A; magnesium stearate; hypromellose

Mode d'administration:

Oral

Unités en paquet:

42

Type d'ordonnance:

(S4) Prescription Only Medicine

indications thérapeutiques:

? Treatment in adults of ringworm (tinea corporis, tinea cruris and tinea pedis) due to infection caused by dermatophytes such as Trichophyton (e.g. T. rubrum, T. mentagrophytes, T. verrucosum, T. violaceum), Microsporum canis and Epidermophyton floccosum, where oral therapy is considered appropriate owing to the site, severity or extent of the infection, and the infection is not responsive to topical therapy. ? Onychomycosis in adults (fungal infection of the nail) caused by dermatophyte fungi.

Descriptif du produit:

Visual Identification: White to off-white, uncoated biconvex, bevelled edge tablet, engraved 'TER' and '250' with a break line on one side and plain on the other; Container Type: Blister Pack; Container Material: PVC/Al; Container Life Time: 24 Months; Container Temperature: Store below 30 degrees Celsius

Statut de autorisation:

Licence status A

Date de l'autorisation:

2014-03-20